Current status of biosimilars in the treatment of inflammatory bowel diseases
Intestinal Research
;
: 15-20, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-77867
ABSTRACT
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden on National Healthcare Systems. The development of first biosimilar to infliximab, CT-P13 (Remsima; Celltrion Inc., Incheon, Korea and Inflextra; Hospiral, Lake Forest, Illinois, USA) has become another way to decrease the medical care cost and increase patient treatment option, but, actual equivalence of efficacy and safety of CT-P13 was investigated in rheumatic diseases only. The extrapolation of outcome from rheumatic trials to IBD and the interchangeability of CT-P13 with infliximab have come to be a matter of concern. Two recent retrospective studies reported the similarity of CT-P13 in terms of efficacy and safety. Infliximab biosimilars may be promising new treatment options for IBD patients, however, well-designed, prospective randomized non-inferiority trials should be needed to confidently integrate infliximab biosimilars into IBD treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Farmacia
/
Árboles
/
Terapia Biológica
/
Enfermedades Inflamatorias del Intestino
/
Colitis Ulcerosa
/
Enfermedad de Crohn
/
Lagos
/
Illinois
/
Enfermedades Reumáticas
/
Estudios Prospectivos
Tipo de estudio:
Estudio observacional
Límite:
Humanos
País/Región como asunto:
America del Norte
/
Asia
Idioma:
Inglés
Revista:
Intestinal Research
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS